Mauro Kazuo Ikeda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mauro Kazuo Ikeda has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Luiz Paulo Kowalski
Head and Neck Surgery Department University of São Paulo Medical School (FMUSP) São Paulo Brazil
2 shared publications - Alessandra Rinaldo
ENT Unit Policlinico Città di Udine Udine Italy
1 shared publication - Alfio Ferlito
Coordinator of the International Head and Neck Scientific Group Padua Italy
1 shared publication - Alvaro Sanabria
Department of Surgery, School of Medicine, Universidad de Antioquia, Medellín, Colombia
1 shared publication - André Lopes Carvalho
Early Detection, Prevention & Infections Branch International Agency for Research on Cancer Lyon France
1 shared publication - Diego Rodrigues Mendonça Silva
AC Camargo Hospital
1 shared publication
Latest Publications
- Open Access
Survival trends of patients with oral and oropharyngeal cancer treated at a cancer center in São Paulo, Brazil
We aimed to estimate the overall survival (OS) and conditional survival (CS) in patients diagnosed with oral and oropharyngeal squamous cell carcinoma (SCC) and to determine their survival trends.The study included all consecutive patients treated at ...
Open AccessSurvival trends of patients with oral and oropharyngeal cancer treated at a cancer center in São Paulo, Brazil
We aimed to estimate the overall survival (OS) and conditional survival (CS) in patients diagnosed with oral and oropharyngeal squamous cell carcinoma (SCC) and to determine their survival trends.The study included all consecutive patients treated at ...
- 24 May 2007
- Published by Wiley in Head & Neck
- Vol. 29 (11) , 1046-1054
Is galectin‐3 a good method for the detection of malignancy in patients with thyroid nodules and a cytologic diagnosis of “follicular neoplasm”? A critical appraisal of the evidence
Background.: Thyroid nodules are the most common surgical disease of the thyroid. Fine‐needle aspiration biopsy (FNAB) is the most commonly employed tool for establishing a diagnosis. However, 15% to 25% of FNAB reports yield inconclusive results. Immunostaining of cytological smears from FNAB with galectin‐3 has been proposed as a tool for differentiating between benign and malignant nodules. We performed a systematic review to evaluate the utility of galectin‐3.Methods.: Prospective studies of nodules with FNAB reports of “follicular neoplasm” and with a definitive diagnosis confirmed by histopathology were selected. Calculations of individual sensitivity, specificity, and positive and negative likelihood ratios were made.Results.: The articles selected were those with the best methodological quality.Conclusion.: Galectin‐3 could be a good tool to guide therapeutic decision in patients with thyroid nodules and FNAB results of follicular neoplasm, but available information has methodological flaws that precludes a definitive answer about galectin‐3 utility in the clinical setting. © 2007 Wiley Periodicals, Inc. Head Neck 2007
- 24 May 2007
- Published by Wiley in Head & Neck
- Vol. 29 (11) , 1046-1054
Is galectin‐3 a good method for the detection of malignancy in patients with thyroid nodules and a cytologic diagnosis of “follicular neoplasm”? A critical appraisal of the evidence
Background.: Thyroid nodules are the most common surgical disease of the thyroid. Fine‐needle aspiration biopsy (FNAB) is the most commonly employed tool for establishing a diagnosis. However, 15% to 25% of FNAB reports yield inconclusive results. Immunostaining of cytological smears from FNAB with galectin‐3 has been proposed as a tool for differentiating between benign and malignant nodules. We performed a systematic review to evaluate the utility of galectin‐3.Methods.: Prospective studies of nodules with FNAB reports of “follicular neoplasm” and with a definitive diagnosis confirmed by histopathology were selected. Calculations of individual sensitivity, specificity, and positive and negative likelihood ratios were made.Results.: The articles selected were those with the best methodological quality.Conclusion.: Galectin‐3 could be a good tool to guide therapeutic decision in patients with thyroid nodules and FNAB results of follicular neoplasm, but available information has methodological flaws that precludes a definitive answer about galectin‐3 utility in the clinical setting. © 2007 Wiley Periodicals, Inc. Head Neck 2007